Benzinga - by Lisa Levin, Benzinga Editor.
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. I think it’s got to come down a little because the stock is losing a lot of money."
Dell Technologies Inc. (NYSE: DELL) is "terrific." Cramer said. "Buy some here and then wait for a little bit of pullback."
Cramer said Cencora, Inc. (NYSE: COR) is a terrific company and recommended buying the same. "This is one of the few stocks in the healthcare business that is holding up," he added.
"I think Tony Xu is just a fantastic manger," Cramer said when asked about DoorDash, Inc. (NASDAQ: DASH). "The stock has had a giant run, it’s only a point from its high. Let’s be a little bit careful, Buy some and then let it come lower."
Don’t forget to check out our premarket coverage here
The "Mad Money" host recommended buying The Boeing Company (NYSE: BA).
"Boeing’s going higher. I think that this is their year. Last year, they had supply chain problems and a couple snafus with some planes. Now it seems to be clearer sailing," he added.
When asked about T-Mobile US, Inc. (NYSE: TMUS), he said, "I would not worry about those lawsuits at all. I think Mike Sievert has it totally under control, and I think that T-Mobile represents great value, even up here."
Cramer said Cardinal Health, Inc. (NYSE: CAH) is a great stock to own at this stage of the economy. "I am so impressed with the people from Cardinal. They have gotten it right after being in the wilderness for a bit," he noted.
Cramer said he likes Macy's, Inc. (NYSE: M) stock very much. "It could be the next Gap stores, I mean when it comes to the trajectory of the stock," he noted.
Price Action: Shares of Macy’s gained 0.4% to close at $14.96, while Cardinal Health fell 0.5% to $106.16 on Tuesday. T-Mobile fell 0.3% to $148.38, while Boeing rose 1.4% to $222.37 during Tuesday’s session. DoorDash gained 0.5% to $94.44, while Cencora shares fell 0.2% to settle at $201.30, while Dell fell 0.6% on Tuesday. CRISPR Therapeutics shares fell 1.3% to settle at $70.66 on Tuesday.
Now Read This: Dollar Tree, Salesforce And 3 Stocks To Watch Heading Into Wednesday
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.